Bristol-Myers Squibb
Develops medicines for cancer, blood disorders, immunology, cardiovascular disease and neuroscience.
Something off on this page? Send us feedback.
Profile
Develops and commercializes prescription medicines across oncology, hematology, immunology, cardiovascular disease and neuroscience, led by Eliquis and Opdivo. Most revenue comes from the United States, while growth depends on launches and licensed or acquired assets replacing products exposed to patent expiry and generic or biosimilar competition.
Discovers, develops, licenses, manufactures and sells prescription medicines across oncology, hematology, immunology, cardiovascular disease and neuroscience. The portfolio spans small molecules and biologics, including Opdivo and Yervoy in cancer, Eliquis in cardiovascular care, Orencia and Sotyktu in immunology, Cobenfy in neuroscience, and the CAR-T therapies Breyanzi and Abecma.
Commercial scale, specialist sales teams and dedicated manufacturing for biologics and cell therapies support launches worldwide; the United States supplies most revenue. Business development remains integral, from acquired products and platforms to collaborations such as the Eliquis alliance with Pfizer.
Operates as one biopharmaceutical segment. Revenue depends heavily on a few medicines, while patent expirations, generic and biosimilar entry, regulatory approval, government pricing and reimbursement, and specialized manufacturing govern the portfolio’s economics.
Company facts
Key statistics
Year to date +24.5% · Average volume (30d) 10.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Raymond James | Initiate | Strong Buy | |||
| Aug 5, 2026 | Cowen & Co. | Initiate | Buy | |||
| Aug 5, 2026 | Bernstein | Upgrade | Market Perform | Outperform | ||
| Aug 5, 2026 | UBS | Downgrade | Buy | Neutral | ||
| Aug 5, 2026 | Roth Capital | Initiate | Buy | $75 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $1.60 | $2.04 | +27.5% | $11.74B | $12.97B | +10.5% | +2.79% |
| Apr 30, 2026Q1 FY26 | $1.42 | $1.58 | +11.3% | $10.93B | $11.49B | +5.1% | −3.91% |
| Feb 5, 2026Q4 FY25 | $1.23 | $1.26 | +2.4% | $12.28B | $12.50B | +1.8% | +4.15% |
| Oct 30, 2025Q3 FY25 | $1.52 | $1.63 | +7.2% | $11.85B | $12.22B | +3.1% | +0.99% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $11.20B | $12.27B | $12.22B | $12.50B | $11.49B | $12.97B | |
| Gross profit | $8.17B | $8.90B | $8.79B | $8.41B | $8.07B | $9.25B | |
| Operating income | $3.50B | $3.77B | $3.64B | $2.81B | $3.37B | $4.09B | |
| Net income | $2.46B | $1.31B | $2.20B | $1.09B | $2.68B | $3.32B | |
| Diluted EPS | $1.20 | $0.64 | $1.08 | $0.53 | $1.31 | $1.62 | |
| Gross margin | 72.9% | 72.5% | 71.9% | 67.2% | 70.2% | 71.3% | |
| Operating margin | 31.2% | 30.8% | 29.8% | 22.5% | 29.3% | 31.5% |
Fiscal years (4-quarter sums)FY21 $46.39B · FY22 $46.16B · FY23 $45.01B · FY24 $48.30B · FY25 $48.20B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $11.07B · Total debt $43.12B · Total assets $87.63B · Shareholders' equity $22.32B
Dividends
Raised for 52 straight years — most recently to $0.63 from $0.62 in Jan 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 2, 2026 | Jul 2 | Aug 3 | $0.63 | |
| Apr 2, 2026 | Apr 2 | May 1 | $0.63 | |
| Jan 2, 2026 | Jan 2 | Feb 2 | $0.63 | raised from $0.62 |
| Oct 3, 2025 | Oct 3 | Nov 3 | $0.62 | |
| Jul 3, 2025 | Jul 3 | Aug 1 | $0.62 | |
| Apr 4, 2025 | Apr 4 | May 1 | $0.62 | |
| Jan 3, 2025 | Jan 3 | Feb 3 | $0.62 | raised from $0.60 |
| Oct 4, 2024 | Oct 4 | Nov 1 | $0.60 |
Ownership
Shares outstanding 2.04B · Float 2.04B · 99.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 180.38M | 8.83% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 133.34M | 6.53% | 13F | Aug 13, 2026 |
| State Street Corp | 102.41M | 5.01% | 13F | Aug 7, 2026 |
| JPMorgan Chase & Co | 71.71M | 3.51% | 13F | Aug 12, 2026 |
| Charles Schwab Investment Management Inc | 67.60M | 3.31% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 25, 2026 | Phil M. Holzer | officer: SVP and Controller | −500 | $67.50 |
| Apr 1, 2026 | David V. Elkins | officer: EVP, Chief Financial Officer | −30,000 | $61.67 |
| Sep 2, 2025 | David V. Elkins | officer: EVP, Chief Financial Officer | −56,000 | $47.33 |
Peers
- Merck
PD-1 arch-rival; Keytruda vs Opdivo across all major solid-tumor indications.
- Johnson & Johnson
Darzalex dominates myeloma; Carvykti leads Abecma in BCMA CAR-T market share.
- AbbVie
Rinvoq/Skyrizi vs Orencia/Sotyktu; Imbruvica/Venclexta vs BMS hematology.
- Pfizer
Alliance partner on Eliquis; broader oncology and cardiovascular rival.
- Novartis (ADR)
RLT leader (Pluvicto vs RayzeBio); Kymriah vs Breyanzi in CD19 CAR-T.
- AstraZeneca (ADR)
Oncology rival in NSCLC (Tagrisso, Imfinzi) and expanding ADC pipeline.
- Amgen
Lumakras vs Krazati in KRAS G12C; Otezla acquirer; Kyprolis + Enbrel peer.
- Gilead Sciences
Yescarta + Tecartus vs Breyanzi in CD19 CAR-T; anito-cel vs Abecma coming.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Merck | $148.19 | −0.08% | $366.18B | 118.7 | 17.2 | 5.5 | +5.1% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Pfizer | $27.95 | −0.04% | $159.36B | 36.9 | 10.0 | 2.5 | +2.6% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Amgen | $430.27 | −0.49% | $233.38B | 26.9 | 18.4 | 6.1 | +9.7% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Median | 31.1 | 16.6 | 5.7 | +6.5% |